Research and

development

Understanding the CONFO® technology​

Many conformations of GPCRs are unstable in the absence of cytosolic signalling proteins, representing key challenges for current HTS screening efforts. CONFO® bodies are small (15 kDa) and stable single domain fragments harbouring full antigen-binding capacity of the original heavy chain–only antibodies that naturally occur in camelids. CONFO® bodies recognize discontinuous amino acid segments on native proteins, making them ideal tools to selectively stabilize specific conformational states of (membrane) proteins.​

Figure 2: Confobodies® lock therapeutic targets into unique druggable conformations and reveal occluded structural features that are relevant for drug discovery.